Effect of dexamethasone and hyaluronic acid combination on Meniere's disease

Therapeutic effect of intratympanic dexamethasone and hyaluronic acid combination on Meniere's disease patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130311012782N25

Enrollment

Registered

2018-12-07

Start date

2018-01-01

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meniere's disease. Meniere's disease

Interventions

The intervention group: Receives two intratympanic injections of 0.3 ml dexamethasone (manufacture by Abidi company) and 0.2 ml hyaluronic acid (Hyalgan manufacture by Fidia Pharma USA) as a mixture a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Meniere's disease Patients resistant to other treatments such as lifestyle modifications, vasodilators or diuretics during the last 6 months

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hearing impairment. Timepoint: Before the intervention and 2 weeks after the treatment. Method of measurement: Speech discrimination score.;Vertigo. Timepoint: Before the intervention and 2 weeks after the treatment. Method of measurement: Dizziness Handicap Inventory.;Tinnitus. Timepoint: Before the intervention and 2 weeks after the treatment. Method of measurement: Tinnitus Handicap Inventory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Assadpour

Esfahan University of Medical Sciences

leilaasadpour35@gmail.com+98 31 3668 8597

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026